about
A mutation in a functional Sp1 binding site of the telomerase RNA gene (hTERC) promoter in a patient with Paroxysmal Nocturnal HaemoglobinuriaEvasion of anti-growth signaling: A key step in tumorigenesis and potential target for treatment and prophylaxis by natural compounds.Broad targeting of angiogenesis for cancer prevention and therapyTherapeutic targeting of replicative immortalityA multi-targeted approach to suppress tumor-promoting inflammationMathematical model of a telomerase transcriptional regulatory network developed by cell-based screening: analysis of inhibitor effects and telomerase expression mechanismsDynamic telomerase gene suppression via network effects of GSK3 inhibitionScoring of senescence signalling in multiple human tumour gene expression datasets, identification of a correlation between senescence score and drug toxicity in the NCI60 panel and a pro-inflammatory signature correlating with survival advantage inProperties of a telomerase-specific Cre/Lox switch for transcriptionally targeted cancer gene therapy.Genomic instability in human cancer: Molecular insights and opportunities for therapeutic attack and prevention through diet and nutrition.Drug insight: Cancer cell immortality-telomerase as a target for novel cancer gene therapies.Broad targeting of resistance to apoptosis in cancer.Targeting the telomere and shelterin complex for cancer therapy: current views and future perspectives.Cancer cell senescence: a new frontier in drug development.MicroRNA and senescence: the senectome, integration and distributed control.Activation of telomerase rna gene promoter activity by NF-Y, Sp1, and the retinoblastoma protein and repression by Sp3.Tissue invasion and metastasis: Molecular, biological and clinical perspectives.Plasma N-acetyl-glucosaminidase in advanced gastro-intestinal adenocarcinoma correlates with age, stage and outcome.TCEAL7 inhibition of c-Myc activity in alternative lengthening of telomeres regulates hTERT expression.A gene expression signature classifying telomerase and ALT immortalization reveals an hTERT regulatory network and suggests a mesenchymal stem cell origin for ALT.Modulation of telomerase promoter tumor selectivity in the context of oncolytic adenoviruses.Transcriptional repression of telomerase RNA gene expression by c-Jun-NH2-kinase and Sp1/Sp3.Hypoxic regulation of telomerase gene expression by transcriptional and post-transcriptional mechanisms.Synthetic anticancer gene medicine exploits intrinsic antitumor activity of cationic vector to cure established tumors.Involvement of NF-Y and Sp1 binding sequences in basal transcription of the human telomerase RNA gene.Telomerase-specific suicide gene therapy vectors expressing bacterial nitroreductase sensitize human cancer cells to the pro-drug CB1954.Selective ablation of human cancer cells by telomerase-specific adenoviral suicide gene therapy vectors expressing bacterial nitroreductase.Modulation of gene expression using zinc finger-based artificial transcription factors
P50
Q24799321-297D6043-9DB7-465F-8F81-804B19D198E4Q26827810-5385D994-4841-4824-B6D1-B7328AC5A7DBQ27002903-21704838-6E44-4DE7-B785-ABD77C4DF70BQ27027457-2CB0EF1E-D504-435C-A675-38E2B96F10D8Q28393278-F597AC73-570B-4A03-8C7C-3ED1E7980E6DQ28539760-4BC38506-A220-4DB6-AA75-F8F22A7DF844Q33489588-863C731C-F794-4D5A-97DD-0667544F7246Q33710045-7B991C18-5C09-4563-A8D3-2EBF7930EBD5Q34769921-10B2FF0C-6C96-4E76-968B-2BE37F1B38C5Q36144711-44B7485D-E6FE-4418-9C4D-0F2BE564823AQ36303872-BDD69113-3964-45A6-A5BB-2E6512E767BEQ36483749-16A0479F-4624-462B-A1D5-555DE4FF58D5Q37825614-565B92AE-14E3-4BBD-ABFB-C4F0DD05AFA3Q37982201-1116BEB3-08BB-4849-A434-07E6F080E374Q38101362-49ABF9F4-B455-4BD1-AB45-2598C3F94331Q38303623-8406B124-99E1-41E1-8445-EEFBB504819DQ38417443-E2094A6C-42E5-48BC-8343-29FE7EE77E01Q39157414-84680590-FE11-4C67-B923-04BF8080298DQ39705986-8F24590E-53E9-4F24-BF56-5EB12892BC7DQ39811985-92F3DA3A-08DC-4AA4-A437-F7C2587AC789Q40174145-CC81A070-99A6-47AA-8F08-06A611260445Q40322106-6381B9C6-1E04-4ECC-B701-D0A69AA6DCB7Q40371754-615128AA-1C5C-427A-BC40-C015E7E4692DQ40372923-7599BD6D-BFDD-4A3D-9B08-FC76E5C5118EQ42437075-53228D4F-0866-45C0-9CF6-38F057FE0E29Q43831003-AD85A590-A7EA-4E78-A11C-399F37E46FCBQ44289559-7D8D2292-3844-4848-B1D0-FBCEA3C1F6FEQ84642831-4D2E8108-0202-4014-B333-1EC7ADB7AD58
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Alan E Bilsland
@ast
Alan E Bilsland
@en
Alan E Bilsland
@es
Alan E Bilsland
@nl
Alan E Bilsland
@sl
type
label
Alan E Bilsland
@ast
Alan E Bilsland
@en
Alan E Bilsland
@es
Alan E Bilsland
@nl
Alan E Bilsland
@sl
prefLabel
Alan E Bilsland
@ast
Alan E Bilsland
@en
Alan E Bilsland
@es
Alan E Bilsland
@nl
Alan E Bilsland
@sl
P106
P21
P31
P496
0000-0003-0957-3908